PTC Therapeutics Completes $550 Million Convertible Notes Offering

PTC Therapeutics Completes $550 Million Convertible Notes Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
We guide clients through today’s ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

PTC Therapeutics, Inc. (NASDAQ: PTCT), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders, announced the pricing and closing of a $550 million offering of 0% Convertible Senior Notes due 2031 pursuant to Rule 144A under the Securities Act of 1933, as amended.

WilmerHale advised PTC in the offering.

The WilmerHale team was led by Brian Johnson and Andrea Sorrentino and included Rachael Joseph, Sam Wizon, Brandon Hornlein, Nathan Moore and Meghan Walsh.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel